Baseline characteristics
| Case . | Sex . | Age, y . | Bone marrow histology . | MYD88 L265p mutation . | Total IgM, g/L . | Previous treatment . | Hb, g/dL, at start of ibrutinib . | Duration of ibrutinib treatment at time of data collection (mo) . |
|---|---|---|---|---|---|---|---|---|
| 1 | M | 73 | CLL | ND | 7 | Steroids, IVIG† | 7.5* | 17 |
| 2 | M | 66 | CLL | ND | 0.9 | Steroids, rituximab, fludarabine | 11.2 | 12 |
| 3 | M | 58 | CLL | ND | 0.3 | None | 8.8* | 24 |
| 4‡ | M | 66 | CLL | ND | 0.4 | Steroids, rituximab†§ | 6.0* | 2 |
| 5¶ | M | 85 | CLL | ND | ND | Steroids, rituximab, chlorambucil-obinutuzumab, MMF | 9.0* | 15 |
| 6 | M | 81 | SLL | ND | 1.5 | rituximab, bendamustine, bortezomib† | 6.9* | 29 |
| 7 | F | 67 | CAD | Negative | 4.4 | Rituximab, bendamustine, fludarabine | 8.2 | 10 |
| 8 | M | 71 | CAD | Negative | 26 | Steroids, DRC, rituximab | 11.9‖ | 10 |
| 9 | F | 81 | CAD | ND | 1.0 | Steroids, rituximab, chlorambucil | 9.0* | 3 |
| 10 | F | 72 | CAD | ND | 2.1 | Rituximab (3 cycles),† DRC, darbepoetin† | 5.0* | 6 |
| 11 | M | 67 | LPL/WM | Negative | 25 | Rituximab, DRC, rituximab-maintenance | 9.2* | 82 |
| 12 | F | 66 | LPL/WM | Negative | 12 | Rituximab | 7.2* | 60 |
| 13 | F | 71 | LPL/WM | Positive | 27 | Plasmapheresis† | 8.2* | 39 |
| 14 | F | 55 | LPL/WM | Positive | 66.2 | Steroids | 5.9* | 12 |
| 15 | F | 68 | LPL/WM | Positive | 32.7 | Steroids, rituximab (2 cycles), bortezomib-DRC, ixazomib | 10.6‖ | 6 |
| Median (range) | 68(55-85) | 5.7(0.3-66.2) | 3(0-5) | 8.2(5.0-11.9) | 12(3-82) |
| Case . | Sex . | Age, y . | Bone marrow histology . | MYD88 L265p mutation . | Total IgM, g/L . | Previous treatment . | Hb, g/dL, at start of ibrutinib . | Duration of ibrutinib treatment at time of data collection (mo) . |
|---|---|---|---|---|---|---|---|---|
| 1 | M | 73 | CLL | ND | 7 | Steroids, IVIG† | 7.5* | 17 |
| 2 | M | 66 | CLL | ND | 0.9 | Steroids, rituximab, fludarabine | 11.2 | 12 |
| 3 | M | 58 | CLL | ND | 0.3 | None | 8.8* | 24 |
| 4‡ | M | 66 | CLL | ND | 0.4 | Steroids, rituximab†§ | 6.0* | 2 |
| 5¶ | M | 85 | CLL | ND | ND | Steroids, rituximab, chlorambucil-obinutuzumab, MMF | 9.0* | 15 |
| 6 | M | 81 | SLL | ND | 1.5 | rituximab, bendamustine, bortezomib† | 6.9* | 29 |
| 7 | F | 67 | CAD | Negative | 4.4 | Rituximab, bendamustine, fludarabine | 8.2 | 10 |
| 8 | M | 71 | CAD | Negative | 26 | Steroids, DRC, rituximab | 11.9‖ | 10 |
| 9 | F | 81 | CAD | ND | 1.0 | Steroids, rituximab, chlorambucil | 9.0* | 3 |
| 10 | F | 72 | CAD | ND | 2.1 | Rituximab (3 cycles),† DRC, darbepoetin† | 5.0* | 6 |
| 11 | M | 67 | LPL/WM | Negative | 25 | Rituximab, DRC, rituximab-maintenance | 9.2* | 82 |
| 12 | F | 66 | LPL/WM | Negative | 12 | Rituximab | 7.2* | 60 |
| 13 | F | 71 | LPL/WM | Positive | 27 | Plasmapheresis† | 8.2* | 39 |
| 14 | F | 55 | LPL/WM | Positive | 66.2 | Steroids | 5.9* | 12 |
| 15 | F | 68 | LPL/WM | Positive | 32.7 | Steroids, rituximab (2 cycles), bortezomib-DRC, ixazomib | 10.6‖ | 6 |
| Median (range) | 68(55-85) | 5.7(0.3-66.2) | 3(0-5) | 8.2(5.0-11.9) | 12(3-82) |
CAD, primary cold agglutinin disease; CLL, chronic lymphatic leukemia; DRC, dexamethasone, rituximab, cyclophosphamide; F, female; IVIG, intravenous immunoglobulin; LPL, lymphoplasmacytic lymphoma; M, male; MMF, mycophenolate mofetil; ND, not determined; SLL, small lymphocytic lymphoma; WM, Waldenström macroglobulinemia.
Transfusion dependent at start ibrutinib therapy.
Therapy received within 3 months before start ibrutinib therapy.
After 2.5 months of ibrutinib therapy, patient switched to intensive chemotherapy because of the diagnosis of a Richter’s transformation.
Patient was treated with C1 inhibitor (Cinryze), a one-time gift of vincristine, and plasmapheresis within 2 weeks after the start of ibrutinib.
Patient started on ibrutinib therapy because of disabling acrocyanosis in the absence of hemolytic anemia.
Patient died of melanoma (diagnosed prior to initiation of ibrutinib).